🚨 New from #SABCS2024: Dr. Komal Jhaveri presents Phase III #EMBER3 trial results!
Imlunestrant, both as monotherapy & combo with Abemaciclib, shows improved PFS in ER+/HER2- advanced breast cancer.
#oncology #breastcancer #clinicaltrials ascopost.com/videos/2024-...
Dr. Debu Tripathy discusses some of the most impactful findings shared at SABCS, from advances in endocrine therapy, HER2-targeted treatments, PI3K inhibition & nausea control.
🎧 Listen (all channels) or 🔗 buff.ly/JSxqomz
#BCSM #SABCS2024 #Webinar
Palbociclib shows major promise in first-line maintenance for HER2+ breast cancer with a 15-month PFS boost. 💊 Also, active monitoring proves effective for low-risk DCIS, sparing surgery. #SABCS2024 #BreastCancer ascopost.com/news/februar...
Adjuvant chest wall irradiation post-mastectomy in patients with intermediate-risk #breastcancer does not improve 10-year overall survival, according to highly anticipated data presented at #SABCS2024. ow.ly/gG9550UVLqi
A study presented at #SABCS2024 suggests risk-reducing surgeries (breast and/or ovaries) in #BRCA carriers with early #breastcancer reduce the risk of recurrence, reduce the chance of new breast and/or ovarian cancer, & lower mortality risk. Learn more at: www.healio.com/news/hematol...
Neoadjuvant SHR-A1811 Produces pCRs in Early HER2+ Breast Cancer @sabcs.bsky.social #SABCS2024 #bcsm #oncology www.onclive.com/view/neoadju...
Finding Strength in Community: The Power of a Tribe on the Cancer Journey – Judy Medeiros Fitzgerald
oncodaily.com/blog/judy-me...
#BrainCancerSurvivor #BreastCancer #Cancer #Medicine #CancerSurvivor #OncoDaily #Oncology #SABCS #SABCS2024 #Sisters4Prevention #Health
@idisbaepigen.bsky.social presenta avenços al Simposi sobre #CàncerdeMama de San Antonio #SABCS2024 @idisba.bsky.social https://s.mtrbio.com/aiecsbmqym
@idisbaepigen.bsky.social presenta avances en el Simposio sobre #CáncerdeMama de San Antonio #SABCS2024 @idisba.bsky.social https://s.mtrbio.com/ymsmspjybx
Kudos to Dr Krop for. Great balanced discussion. MRD testing has great promise but also brings great potential for harm. Success of any MRD test is inextricably linked to success of our therapeutic interventions. We’re just not there yet.
Bottom line…don’t do it
#SABCS2024
Delighted to present our work on NK cells in metastatic HER2+ breast cancer @ The San Antonio Breast Cancer Symposium 2024!
Work is funded by The Cancer Clinical Research Trust and The Caroline Foundation. @dcu-lsi.bsky.social @dcuresearch.bsky.social #sabcs2024
Hard to get excited or see a future for atezo in breast
Neg results for EFS in GerparDouze, neg adjuvant Impassion 030, no benefit with paclitaxel in MBC
No spin here, time to move in and conclude pembro just makes gut be better in our disease
#SABCS2024
Fabulous plenary from Dr. Pedram Razavi #sabcs2024 on robust and innovative ai models to separate cdk4/6i responders from non-responders.
Thoughtful discussion of #ZEST trial & #ctDNA by Dr Krop in early #Breastcancer - bottom line NOT IN CLINIC YET @SABCSSanAntonio #SABCS2024 @oncodaily.bsky.social @oncodaily.bsky.social
Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊
#SABCS2024 @sabcs.bsky.social
Estudo apresentado hoje na #sabcs2024
Obesidade ao diagnóstico está relacionado a maior risco de recidiva e metástases do #cancerdemama
Jean Wright, MD, FASTRO, stands at the podium at the San Antonio Breast Cancer Symposium, where she presented data from the NRG/RTOG 9804 and ECOG-ACRIN E5194 trials that showed breast-conserving surgery paired with tamoxifen reduced the chances of low-risk DCIS from recurring in the same breast. #SABCS2024
Jean Wright, MD, FASTRO, presented data from the NRG/RTOG 9804 and ECOG-ACRIN E5194 trials that showed breast-conserving surgery paired with tamoxifen reduced the chances of low-risk DCIS from recurring in the same breast. #SABCS2024 @sabcs.bsky.social
Thanks to those who stopped by for our International cardio-oncology society (ICOS) reception during
the 2024 SABCS symposium #sabcs2024
Fantastic event held yesterday by the @oncbrothers.bsky.social - truly thought provoking discussion with giants in the breast cancer space! Honored to be apart of it! @neil-iyengarmd.bsky.social @laurahuppert.bsky.so
@drsgraff.bsky.social
#sabcs2024 #signifymd
Hyping for my smart dear friend @yabdoumd.bsky.social from UNC, who is moderating Poster Spotlight Session 9: ctDNA Uses for Minimal Residual Disease Testing, Tumor Evolution, and Novel Technologies. Tomorrow at 7 AM at Stars at Night 3-4
#SABCS2024
#bcsm
@sabcs.bsky.social
Congratulations to @caiy0219.bsky.social for an excellent poster presentation today! 👏🏽
Also, so happy to be reunited with @reikudo.bsky.social to represent the translational team in @saratchandarlapaty.bsky.social’s lab at #SABCS2024!
Thanks to Alamo Breast Canver Foundation for the chance to debrief with the experts! #sabcs #sabcs2024
ADCs offer so much promise for our patients but still need to understand; sequencing, biomarkers for response , toxicity management and drivers of resistance. #sabcs2024
Fantastic results from EMBER-3 showing response with abemaciclib + imlunestrant with ORR of 35% in combination for ESR1m HR+ adjuvant and ABC patients and specifically showed in those with ESR1m ⬆️PFS from 11.1m to 5.5m with combo vs oral SERD alone. #sabcs2024 @breastcancerdoc.bsky.social
MARGOT trial results presented by Dr Ada Waks at #SABCS2024
No statistically sig pCR benefit (56% vs 46%, p=0.25) between preop margetuximab vs. trastuzumab in combination with paclitaxel-pertuzumab in pts with HER2+ BC and CD16 genotype FF or FV
@oncoalert.bsky.social
@dfcibreastonc.bsky.social
Don’t miss tomorrow’s poster session, with a stellar team! Honored to present with
@dfcibreastonc.bsky.social #SABCS2024 @sabcs.bsky.social
Need some simplification regarding ovarian suppression in premenopausal women? Nice summary by Prudence Francis from @petermaccc.bsky.social of who are candidates for OS + AI vs tamoxifen and timing of these agents is crucial! #sabcs2024
